Argininosuccinic aciduria: Recent pathophysiological insights and therapeutic prospects

Julien Baruteau, Carmen Diez-Fernandez, Shaul Lerner, Giusy Ranucci, Paul Gissen, Carlo Dionisi-Vici, Sandesh Nagamani, Ayelet Erez, Johannes Häberle

Research output: Contribution to journalArticle

Abstract

The first patients affected by argininosuccinic aciduria (ASA) were reported 60 years ago. The clinical presentation was initially described as similar to other urea cycle defects, but increasing evidence has shown overtime an atypical systemic phenotype with a paradoxical observation, that is, a higher rate of neurological complications contrasting with a lower rate of hyperammonaemic episodes. The disappointing long-term clinical outcomes of many of the patients have challenged the current standard of care and therapeutic strategy, which aims to normalize plasma ammonia and arginine levels. Interrogations have raised about the benefit of newborn screening or liver transplantation on the neurological phenotype. Over the last decade, novel discoveries enabled by the generation of new transgenic argininosuccinate lyase (ASL)-deficient mouse models have been achieved, such as, a better understanding of ASL and its close interaction with nitric oxide metabolism, ASL physiological role outside the liver, and the pathophysiological role of oxidative/nitrosative stress or excessive arginine treatment. Here, we present a collaborative review, which highlights these recent discoveries and novel emerging concepts about ASL role in human physiology, ASA clinical phenotype and geographic prevalence, limits of current standard of care and newborn screening, pathophysiology of the disease, and emerging novel therapies. We propose recommendations for monitoring of ASA patients. Ongoing research aims to better understand the underlying pathogenic mechanisms of the systemic disease to design novel therapies.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalJournal of Inherited Metabolic Disease
DOIs
Publication statusE-pub ahead of print - Feb 5 2019

Fingerprint

Argininosuccinic Aciduria
Argininosuccinate Lyase
Standard of Care
Phenotype
Arginine
Newborn Infant
Therapeutics
Ammonia
Liver Transplantation
Urea
Nitric Oxide
Oxidative Stress
Observation
Liver
Research

Cite this

Argininosuccinic aciduria : Recent pathophysiological insights and therapeutic prospects. / Baruteau, Julien; Diez-Fernandez, Carmen; Lerner, Shaul; Ranucci, Giusy; Gissen, Paul; Dionisi-Vici, Carlo; Nagamani, Sandesh; Erez, Ayelet; Häberle, Johannes.

In: Journal of Inherited Metabolic Disease, 05.02.2019, p. 1-15.

Research output: Contribution to journalArticle

Baruteau, Julien ; Diez-Fernandez, Carmen ; Lerner, Shaul ; Ranucci, Giusy ; Gissen, Paul ; Dionisi-Vici, Carlo ; Nagamani, Sandesh ; Erez, Ayelet ; Häberle, Johannes. / Argininosuccinic aciduria : Recent pathophysiological insights and therapeutic prospects. In: Journal of Inherited Metabolic Disease. 2019 ; pp. 1-15.
@article{e19f18974b174720994b231a08929b65,
title = "Argininosuccinic aciduria: Recent pathophysiological insights and therapeutic prospects",
abstract = "The first patients affected by argininosuccinic aciduria (ASA) were reported 60 years ago. The clinical presentation was initially described as similar to other urea cycle defects, but increasing evidence has shown overtime an atypical systemic phenotype with a paradoxical observation, that is, a higher rate of neurological complications contrasting with a lower rate of hyperammonaemic episodes. The disappointing long-term clinical outcomes of many of the patients have challenged the current standard of care and therapeutic strategy, which aims to normalize plasma ammonia and arginine levels. Interrogations have raised about the benefit of newborn screening or liver transplantation on the neurological phenotype. Over the last decade, novel discoveries enabled by the generation of new transgenic argininosuccinate lyase (ASL)-deficient mouse models have been achieved, such as, a better understanding of ASL and its close interaction with nitric oxide metabolism, ASL physiological role outside the liver, and the pathophysiological role of oxidative/nitrosative stress or excessive arginine treatment. Here, we present a collaborative review, which highlights these recent discoveries and novel emerging concepts about ASL role in human physiology, ASA clinical phenotype and geographic prevalence, limits of current standard of care and newborn screening, pathophysiology of the disease, and emerging novel therapies. We propose recommendations for monitoring of ASA patients. Ongoing research aims to better understand the underlying pathogenic mechanisms of the systemic disease to design novel therapies.",
author = "Julien Baruteau and Carmen Diez-Fernandez and Shaul Lerner and Giusy Ranucci and Paul Gissen and Carlo Dionisi-Vici and Sandesh Nagamani and Ayelet Erez and Johannes H{\"a}berle",
note = "{\circledC} 2018 SSIEM.",
year = "2019",
month = "2",
day = "5",
doi = "10.1002/jimd.12047",
language = "English",
pages = "1--15",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",

}

TY - JOUR

T1 - Argininosuccinic aciduria

T2 - Recent pathophysiological insights and therapeutic prospects

AU - Baruteau, Julien

AU - Diez-Fernandez, Carmen

AU - Lerner, Shaul

AU - Ranucci, Giusy

AU - Gissen, Paul

AU - Dionisi-Vici, Carlo

AU - Nagamani, Sandesh

AU - Erez, Ayelet

AU - Häberle, Johannes

N1 - © 2018 SSIEM.

PY - 2019/2/5

Y1 - 2019/2/5

N2 - The first patients affected by argininosuccinic aciduria (ASA) were reported 60 years ago. The clinical presentation was initially described as similar to other urea cycle defects, but increasing evidence has shown overtime an atypical systemic phenotype with a paradoxical observation, that is, a higher rate of neurological complications contrasting with a lower rate of hyperammonaemic episodes. The disappointing long-term clinical outcomes of many of the patients have challenged the current standard of care and therapeutic strategy, which aims to normalize plasma ammonia and arginine levels. Interrogations have raised about the benefit of newborn screening or liver transplantation on the neurological phenotype. Over the last decade, novel discoveries enabled by the generation of new transgenic argininosuccinate lyase (ASL)-deficient mouse models have been achieved, such as, a better understanding of ASL and its close interaction with nitric oxide metabolism, ASL physiological role outside the liver, and the pathophysiological role of oxidative/nitrosative stress or excessive arginine treatment. Here, we present a collaborative review, which highlights these recent discoveries and novel emerging concepts about ASL role in human physiology, ASA clinical phenotype and geographic prevalence, limits of current standard of care and newborn screening, pathophysiology of the disease, and emerging novel therapies. We propose recommendations for monitoring of ASA patients. Ongoing research aims to better understand the underlying pathogenic mechanisms of the systemic disease to design novel therapies.

AB - The first patients affected by argininosuccinic aciduria (ASA) were reported 60 years ago. The clinical presentation was initially described as similar to other urea cycle defects, but increasing evidence has shown overtime an atypical systemic phenotype with a paradoxical observation, that is, a higher rate of neurological complications contrasting with a lower rate of hyperammonaemic episodes. The disappointing long-term clinical outcomes of many of the patients have challenged the current standard of care and therapeutic strategy, which aims to normalize plasma ammonia and arginine levels. Interrogations have raised about the benefit of newborn screening or liver transplantation on the neurological phenotype. Over the last decade, novel discoveries enabled by the generation of new transgenic argininosuccinate lyase (ASL)-deficient mouse models have been achieved, such as, a better understanding of ASL and its close interaction with nitric oxide metabolism, ASL physiological role outside the liver, and the pathophysiological role of oxidative/nitrosative stress or excessive arginine treatment. Here, we present a collaborative review, which highlights these recent discoveries and novel emerging concepts about ASL role in human physiology, ASA clinical phenotype and geographic prevalence, limits of current standard of care and newborn screening, pathophysiology of the disease, and emerging novel therapies. We propose recommendations for monitoring of ASA patients. Ongoing research aims to better understand the underlying pathogenic mechanisms of the systemic disease to design novel therapies.

U2 - 10.1002/jimd.12047

DO - 10.1002/jimd.12047

M3 - Article

C2 - 30723942

SP - 1

EP - 15

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

ER -